Kevin Dai, PharmD is a Managing Director at Vivo Capital, where he invests across Seed, Series A, Growth, Private Equity, and Post-IPO stages in sectors including Healthcare, Biotechnology, Pharmaceuticals, Oncology, Medical Devices, Health IT, Digital Health, and Health & Hospital Services. He invests in companies in the United States (with a focus on California and the San Francisco Bay Area), the broader Western US, and across Asia Pacific including Taiwan and Greater China. He has invested in companies like ADARx Pharmaceuticals, Zenas Biopharma, ALX Oncology, Bolt Biotherapeutics, and Proteologix. Before Vivo Capital, he was an Equity Research Associate (Healthcare/Biotechnology) at Canaccord Genuity, a Clinical Oncology Pharmacy Specialist (Hematology/Oncology) at Memorial Sloan Kettering Cancer Center, and a Research Intern (Biochemistry) at Merck. Kevin earned his PharmD from Rutgers University and resides in the San Francisco Bay Area.
Kevin Dai, PharmD, Managing Director @ Vivo. Profile with intro opportunities and ranking information.
Not Yet Mapped
We've created a profile for Kevin Dai, PharmD from Vivo Capital. Our ranking analysis and additional data will be available once our research is complete.
Rankings and detailed information coming soon
Network Strength
No ranking data available yet.
How to get an intro to Kevin
Map your path to Kevin instantly
Connect your network and Draftboard will automatically find and score the strongest paths to Kevin
That's it. Draftboard does the rest.
Rankings based on connection strength analysis - we ONLY show aggregate data, never specific connection data.